<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963649</url>
  </required_header>
  <id_info>
    <org_study_id>APV-IN.PACT BTK OUS</org_study_id>
    <nct_id>NCT02963649</nct_id>
  </id_info>
  <brief_title>IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA</brief_title>
  <official_title>Randomized Study of IN.PACT 014 Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter vs. Standard Percutaneous Transluminal Angioplasty for the Treatment of Chronic Total Occlusions in the Infrapopliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of the paclitaxel drug-eluting balloon IN.PACT 014 versus
      conventional percutaneous transluminal angioplasty (PTA) for the treatment of patients with
      chronic total occlusions in the infrapopliteal arteries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Late lumen loss (LLL) at 9 months</measure>
    <time_frame>9 Months</time_frame>
    <description>Late lumen loss (LLL) at 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Safety Endpoint</measure>
    <time_frame>9 Months</time_frame>
    <description>A composite of freedom from device- and procedure-related mortality within 30 days, freedom from major target limb amputation and freedom from clinically-driven TLR within 9 months post-index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event (MAE) rate</measure>
    <time_frame>through 3, 6, 9, 12, 24 and 36 months</time_frame>
    <description>Major Adverse Event (MAE) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of wound healing</measure>
    <time_frame>at 30 days, 3, 6, 9, 12, 24 and 36 months</time_frame>
    <description>completely healed - improvement - unchanged - worsened</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis at the target lesion</measure>
    <time_frame>through 30 days, 3, 6, 9, 12, 24 and 36 months</time_frame>
    <description>Thrombosis at the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>at the time of procedure</time_frame>
    <description>is defined as successful drug delivery, balloon inflation, deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>up to discharge visit</time_frame>
    <description>is defined as residual stenosis of ≤ 30% without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or TVR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>drug-eluting balloon IN.PACT 014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard angioplasty balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard PTA balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DCB</intervention_name>
    <description>Drug Coated Balloon</description>
    <arm_group_label>drug-eluting balloon IN.PACT 014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA</intervention_name>
    <description>Percutaneous Transluminal Angioplasty</description>
    <arm_group_label>Standard angioplasty balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years.

          2. Subject has been informed of the nature of the study, agrees to participate and has
             signed an EC approved consent form.

          3. Female subjects of childbearing potential have a negative pregnancy test ≤7 days
             before the procedure and are willing to use a reliable method of birth control for the
             duration of study participation;

          4. Subject has documented chronic Critical Limb Ischemia (CLI) in the target limb prior
             to the study procedure with Rutherford Clinical Category 4 or 5 .

          5. Life expectancy &gt;1 year in the Investigator's opinion.

          6. Reference Vessel Diameter (RVD) 2 - 4 mm, based on visual estimation.

          7. Presence of documented run-off to the foot

          8. Inflow free from flow-limiting lesion confirmed by angiography.

          9. Successful pre-dilatation of the (entire) target lesion.

        Exclusion Criteria:

          1. Subject unwilling or unlikely to comply to the appropriate follow-up times for the
             duration of the study.

          2. Prior stent(s) or bypass surgery within the target vessel(s) (including stents placed
             within target vessels during the index procedure prior to randomization.

          3. Previous DCB of the target vessel within 6 months prior to index procedure.

          4. Aneurysm in the target vessel.

          5. Angiographic evidence of thrombus within target limb.

          6. Recent MI or stroke &lt; 30 days prior to the index procedure.

          7. Heart failure with Ejection Fraction &lt; 30%.

          8. Impaired renal function (GFR &lt;30 mL/min) and patients on dialysis.

          9. Subject with vasculitis, systemic Lupus Erythematosus or Polymyalgia Rheumatica on
             active treatment.

         10. Patient receiving systemic corticosteroid therapy.

         11. Known allergies or sensitivities to heparin, aspirin (ASA), other
             anticoagulant/anti-platelet therapies which could not be substituted, and/or
             paclitaxel or an allergy to contrast media that cannot be adequately pre-treated prior
             to the index procedure.

         12. The patient is currently enrolled in another investigational device or drug trial that
             is interfering with the endpoints of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stijn Bollen</last_name>
    <phone>+31433566792</phone>
    <email>stijn.bollen@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ Sint Blasius</name>
      <address>
        <city>Dendermonde</city>
        <state>East-Flanders</state>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Deloose, MD</last_name>
      <email>koen.deloose@azsintblasius.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZOL Genk</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Lansink, MD</last_name>
      <email>wouter.lansink@zol.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart</name>
      <address>
        <city>Tienen</city>
        <state>Vlaams Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Keirse, MD</last_name>
      <email>koen.keirse@rztienen.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Vermassen, Professor</last_name>
      <email>frank.vermassen@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Frank Vermassen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Guillaume et Rene Laennec - Centre Hospitalier Universitaire</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Goueffic, MD</last_name>
      <email>yann.goueffic@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Katsanos, MD</last_name>
      <email>katsanos@med.upatras.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Multimedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>Lombardy</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavio Airoldi, MD</last_name>
      <email>flavio.airoldi@multimedica.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <state>Ravenna</state>
        <zip>48033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Micari, MD</last_name>
      <email>antoniomicari@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Micari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Donato</name>
      <address>
        <city>Arezzo</city>
        <zip>50200</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Liistro, MD</last_name>
      <email>francescoliistro@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Reijnen, MD</last_name>
      <email>MReijnen@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Banyai, MD</last_name>
      <email>martin.banyai@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-eluting angioplasty balloon, Drug coated angioplasty balloon, Experimental, percutaneous transluminal angioplasty (PTA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

